# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Following FDA Approval to Commence the Clinical Trial, an Official Site Initiation Has Taken Place as Preparation for Patient E...
- Reuters
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Microbot Medical (NASDAQ:MBOT) with a Buy and maintains $7 pri...